4.7 Article

HER2 Expression in Peritoneal Dissemination of High-Grade Serous Ovarian Carcinoma: A Comparative Study of Immunohistochemical Reactivity Using Four HER2 Antibodies

期刊

JOURNAL OF CLINICAL MEDICINE
卷 11, 期 23, 页码 -

出版社

MDPI
DOI: 10.3390/jcm11236963

关键词

HER2; serous carcinoma; ovary; peritoneum; immunohistochemistry; antibodies

资金

  1. Chungnam National University Sejong Hospital Research Fund
  2. Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea
  3. [2022]
  4. [HR20C0025]

向作者/读者索取更多资源

The study compared the performance of four anti-HER2 antibodies in HGSOC specimens with peritoneal dissemination, finding that 39.5% of cases were positive for at least one HER2 antibody. Detection of HER2 gene amplification was limited, but all four antibodies could be potentially used for patient selection for anti-HER2 therapies targeting HGSOC with peritoneal dissemination.
Most high-grade serous ovarian carcinomas (HGSOCs) involving the peritoneum are aggressive. Epidermal growth factor receptor 2 (HER2) is aberrantly activated in a variety of solid cancers. The HER2 status of a tumor is based on cytoplasmic membrane staining of an intracellular domain (ICD)-specific HER2 antibody. We compared four anti-HER2 antibodies in an immunohistochemical study of HGSOC with peritoneal dissemination. HER2 expression was assessed in peritoneal disseminated HGSOC specimens from 38 patients by immunohistochemistry using four different anti-HER2 antibodies (an ICD antibody (clone A0485), an extracellular domain (ECD) antibody (clone SP3), and two antibodies recognizing HER2 phosphorylated at tyrosine 877 or 1248 (pHER2Y(877) and pHER2Y(1248))). HER2 gene amplification was accessed by chromogenic in situ hybridization (CISH). The antibodies showed HER2 positivity as follows: 31.6% of cases (12/38) with A0485, 26.3% (10/38) with SP3, 7.9% (3/38) with pHER2Y(877), and 21.1% (8/38) with pHER2Y(1248). Fifteen out of thirty-eight (39.5%) cases were positive for at least one of the four HER2 antibodies. HER2 gene amplification was detected in 3/19 cases. All four HER2 antibodies could be used for patient selection for anti-HER2 therapies. These findings raise the possibility of anti-HER2 therapeutic strategies for HGSOC with peritoneal dissemination.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据